Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2)

Findings of the UK national external quality assessment scheme for immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory

Merdol Ibrahim, Andrew Dodson, Sarah Barnett, David Fish, Bharat Jasani, Keith Miller

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

This study focused on recent assessment results from the United Kingdom National External Quality Assessment Scheme for Immunocytochemistry and Fluorescence In-Situ Hybridisation breast hormone receptor module in which participants were asked to demonstrate progesterone receptors (PRs). The slides consisted of 3 infiltrating ductal breast carcinomas, previously classified as a high PR expresser, a moderate to low PR expresser, and a negative tumor. During this assessment, 2 commercial rabbit monoclonal antibodies, SP2 (Lab Vision/NeoMarkers, Fremont, CA), and 1E2 (Ventana, Tucson, AZ) were used by 15% of the participants. The SP2 rabbit monoclonal antibody showed false-positive and nonspecific staining on the previously established PR- tumor. This article highlights the necessity for all clinical laboratories to validate immunohistochemical methods and protocols when using newly marketed antibodies such as SP2; use composite tissue blocks with known levels of tumor expression such as a high, mid, and negative expression; and participate in internal and external quality assessment schemes, which can highlight potential technical issues in laboratory methods.

Original languageEnglish
Pages (from-to)398-409
Number of pages12
JournalAmerican Journal of Clinical Pathology
Volume129
Issue number3
DOIs
Publication statusPublished - Mar 2008
Externally publishedYes

Fingerprint

Progesterone Receptors
Immunohistochemistry
Monoclonal Antibodies
Staining and Labeling
Rabbits
Antibodies
Carcinoma, Ductal, Breast
Neoplasms
Fluorescence In Situ Hybridization
Breast
Hormones

Keywords

  • Antibody validation
  • Breast hormonal receptors
  • Progesterone receptor
  • Quality assurance
  • Rabbit monoclonal antibody
  • SP2

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{78b43d3ec19e405fac80c5e2cc81199c,
title = "Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): Findings of the UK national external quality assessment scheme for immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory",
abstract = "This study focused on recent assessment results from the United Kingdom National External Quality Assessment Scheme for Immunocytochemistry and Fluorescence In-Situ Hybridisation breast hormone receptor module in which participants were asked to demonstrate progesterone receptors (PRs). The slides consisted of 3 infiltrating ductal breast carcinomas, previously classified as a high PR expresser, a moderate to low PR expresser, and a negative tumor. During this assessment, 2 commercial rabbit monoclonal antibodies, SP2 (Lab Vision/NeoMarkers, Fremont, CA), and 1E2 (Ventana, Tucson, AZ) were used by 15{\%} of the participants. The SP2 rabbit monoclonal antibody showed false-positive and nonspecific staining on the previously established PR- tumor. This article highlights the necessity for all clinical laboratories to validate immunohistochemical methods and protocols when using newly marketed antibodies such as SP2; use composite tissue blocks with known levels of tumor expression such as a high, mid, and negative expression; and participate in internal and external quality assessment schemes, which can highlight potential technical issues in laboratory methods.",
keywords = "Antibody validation, Breast hormonal receptors, Progesterone receptor, Quality assurance, Rabbit monoclonal antibody, SP2",
author = "Merdol Ibrahim and Andrew Dodson and Sarah Barnett and David Fish and Bharat Jasani and Keith Miller",
year = "2008",
month = "3",
doi = "10.1309/2YXRLEQVPPNRWHGA",
language = "English",
volume = "129",
pages = "398--409",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2)

T2 - Findings of the UK national external quality assessment scheme for immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory

AU - Ibrahim, Merdol

AU - Dodson, Andrew

AU - Barnett, Sarah

AU - Fish, David

AU - Jasani, Bharat

AU - Miller, Keith

PY - 2008/3

Y1 - 2008/3

N2 - This study focused on recent assessment results from the United Kingdom National External Quality Assessment Scheme for Immunocytochemistry and Fluorescence In-Situ Hybridisation breast hormone receptor module in which participants were asked to demonstrate progesterone receptors (PRs). The slides consisted of 3 infiltrating ductal breast carcinomas, previously classified as a high PR expresser, a moderate to low PR expresser, and a negative tumor. During this assessment, 2 commercial rabbit monoclonal antibodies, SP2 (Lab Vision/NeoMarkers, Fremont, CA), and 1E2 (Ventana, Tucson, AZ) were used by 15% of the participants. The SP2 rabbit monoclonal antibody showed false-positive and nonspecific staining on the previously established PR- tumor. This article highlights the necessity for all clinical laboratories to validate immunohistochemical methods and protocols when using newly marketed antibodies such as SP2; use composite tissue blocks with known levels of tumor expression such as a high, mid, and negative expression; and participate in internal and external quality assessment schemes, which can highlight potential technical issues in laboratory methods.

AB - This study focused on recent assessment results from the United Kingdom National External Quality Assessment Scheme for Immunocytochemistry and Fluorescence In-Situ Hybridisation breast hormone receptor module in which participants were asked to demonstrate progesterone receptors (PRs). The slides consisted of 3 infiltrating ductal breast carcinomas, previously classified as a high PR expresser, a moderate to low PR expresser, and a negative tumor. During this assessment, 2 commercial rabbit monoclonal antibodies, SP2 (Lab Vision/NeoMarkers, Fremont, CA), and 1E2 (Ventana, Tucson, AZ) were used by 15% of the participants. The SP2 rabbit monoclonal antibody showed false-positive and nonspecific staining on the previously established PR- tumor. This article highlights the necessity for all clinical laboratories to validate immunohistochemical methods and protocols when using newly marketed antibodies such as SP2; use composite tissue blocks with known levels of tumor expression such as a high, mid, and negative expression; and participate in internal and external quality assessment schemes, which can highlight potential technical issues in laboratory methods.

KW - Antibody validation

KW - Breast hormonal receptors

KW - Progesterone receptor

KW - Quality assurance

KW - Rabbit monoclonal antibody

KW - SP2

UR - http://www.scopus.com/inward/record.url?scp=41649108476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41649108476&partnerID=8YFLogxK

U2 - 10.1309/2YXRLEQVPPNRWHGA

DO - 10.1309/2YXRLEQVPPNRWHGA

M3 - Article

VL - 129

SP - 398

EP - 409

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -